Testing of Cannabinoid Oil Extracts in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain (NPP)
The cannabinoid class of medications are widely used to treat disease or alleviate symptoms such as spasticity and pain associated with MS. However, the exact molecular mechanisms by which they exert their beneficial effects remain unknown. Recent research and clinical trials demonstrated that cannabinoids may not only alleviate the symptoms of MS, but may also slow the disease progression and delay the onset of symptoms. As such, investigative research is now expanding beyond the traditional paradigms of conventional medicine to now include that of the cannabinoids to the forefront of available treatments for MS. In this research, we aim to investigate the role of cannabinoids in improving myelin repair by beneficially altering the cytokine, chemokine, neurotrophin signalling pathway that has previously been shown to govern myelin repair.